NIH Seeks Licensees for Anti-Inflammatory Compounds Targeting Neurodegenerative Disorders
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
🇬🇧 English
NIH is making a government-owned drug discovery available for licensing and research co-development. The compounds are designed as anti-inflammatory treatments for systemic degenerative and neurodegenerative disorders, and they are still at the pre-clinical stage. The notice matters mainly to pharmaceutical companies, biotech firms, universities, and research partners interested in developing new therapies. Interested parties can contact NIH’s technology transfer office to discuss licensing or co-development opportunities.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- NIH is offering a government-owned family of anti-inflammatory compounds for licensing or research co-development.
- The compounds are positioned as potential treatments for systemic degenerative and neurodegenerative disorders.
- Interested companies and research institutions can contact NIH’s technology transfer office about the opportunity.
Affected Parties
Pharmaceutical and biotech companiesUniversities and research institutions+1 more…
Tags
NIH,drug licensing,anti-inflammatory therapy…